The use of base editing to generate universal off-the-shelf CAR T cells induced durable remissions -- up to 36 months in one ...

Multiple myeloma, a cancer of the bone marrow, remains difficult to treat despite modern CAR T cell therapies. In recent research, a team led by Dr. Armin Rehm presents an improved immunotherapy that ...

What used to be a niche treatment for men with legitimate medical conditions has morphed into "youth and vigor" as a ...

The California Institute for Regenerative Medicine (CIRM) has awarded $7.4 million to support a University of California San Diego team developing a first-of-its-kind stem cell-based gene therapy for ...

The therapy, A2B543, will be added as an arm to the ongoing Phase I/II EVEREST-2 trial, which is testing CAR T-cell products developed using A2's Tmod platform. According to A2, the Tmod platform ...

Cell-based immunotherapies have transformed cancer treatment, yet their widespread use remains constrained by safety risks, ...

Higher levels of CD4-positive naïve T cells in patients receiving CAR T-cell therapy for multiple myeloma are associated with ...

Data presented at ASH 2025 suggest earlier-line use of cilta-cel leads to better outcomes in multiple myeloma because patients have fitter immune systems and less exhausted T cells, improving CAR T ...

In the heart of Waldorf, Maryland, there exists a treasure hunter’s paradise that defies the laws of inflation – Prime Thrift. This sprawling wonderland of pre-loved goods has locals and visitors ...

U.S. IND represents the second regulatory clearance for KLN-1010 and enables the first multi-center clinical trial in the U.S ...

The clearance racks, particularly during seasonal transitions, can yield items in the magical $1.99 to $4.99 range – the kind of prices that make you consider buying backup copies of particularly ...

CAR-T cell therapy provides long, treatment-free remissions for relapsed multiple myeloma, using genetically modified T cells ...